Study of a new test for T-cell lymphoma
Part of Cancer clinical trials.
This trial is testing a new lab test to see how accurately it can detect T-cell lymphoma in stored tissue samples. It looks for specific genetic changes in the T-cells to help confirm or rule out the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a stored tissue sample (FFPE block) with at least 8 thin slices available.
- You must be 18 years or older.
- You must have a diagnosis of T-cell lymphoma (including mycosis fungoides or Sézary syndrome) OR you may have been tested for T-cell lymphoma and found to be negative.
- Your tissue sample must have been preserved using standard formalin (not a substitute like ethanol).
- Up to 20% of samples without T-cell lymphoma can come from normal tissue or other diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This trial tests the safety of a new drug, CX-5461 (Pidnarulex), in people with certain types of aggressive B-cell lymphoma that have specific MYC gene changes. It aims to find out if this drug can help when standard treatments are no longer working.
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new T-Cell Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.